Nakazawa Yosuke, Aoki Miki, Doki Yuri, Morishita Naoki, Endo Shin, Nagai Noriaki, Funakoshi-Tago Megumi, Tamura Hiroomi
Faculty of Pharmacy, Keio University, Tokyo, Japan.
R&D Division, Hayashibara Co., Ltd, Okayama, Japan.
Biochem Biophys Rep. 2020 Dec 26;25:100885. doi: 10.1016/j.bbrep.2020.100885. eCollection 2021 Mar.
Presbyopia is one of the most well-known diseases of the eye, predominantly affecting the adult population after 50 years'. Due to hardening of the lens and failure of accommodative change, patients lose the ability to focus on near objects. This eye symptom is reported to be an early symptom of age-related nuclear cataract, and we have previously reported that hesperetin treatment could delay the onset of nuclear cataractogenesis induced by sodium selenite. In this study, we examined whether oral intake of α-glucosyl-hesperidin (G-Hsd), which has greater water solubility than hesperetin, could delay the onset of presbyopia. G-Hsd treatment protected lens elasticity, upregulated the mRNA expression of anti-oxidative enzymes like glutathione reductase and thioredoxin reductase 1 in the plasma and lens, and prevented premature cataract symptoms in selenite-induced cataract rat lens. Thus, the anti-presbyopic effects of G-Hsd were attributed, at least in part, to its antioxidant effects. G-Hsd represents the first oral treatment agent with anti-presbyopia and/or anti-cataract properties.
老花眼是最广为人知的眼部疾病之一，主要影响50岁以上的成年人。由于晶状体硬化和调节变化功能丧失，患者失去了聚焦于近处物体的能力。据报道，这种眼部症状是年龄相关性核性白内障的早期症状，我们之前也报道过橙皮素治疗可以延缓亚硒酸钠诱导的核性白内障的发生。在本研究中，我们检测了口服α-葡萄糖基橙皮苷（G-Hsd）（其水溶性比橙皮素更高）是否可以延缓老花眼的发生。G-Hsd治疗可保护晶状体弹性，上调血浆和晶状体中抗氧化酶如谷胱甘肽还原酶和硫氧还蛋白还原酶1的mRNA表达，并预防亚硒酸钠诱导的白内障大鼠晶状体出现过早的白内障症状。因此，G-Hsd的抗老花眼作用至少部分归因于其抗氧化作用。G-Hsd是首个具有抗老花眼和/或抗白内障特性的口服治疗药物。
